These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 2122928)

  • 21. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
    Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
    Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer.
    Viens P; Blaise D; Stoppa AM; Brandely M; Baume D; Olive D; Resbeut M; Delpero JR; Lopez M; Aubert C
    J Immunother (1991); 1992 Apr; 11(3):218-24. PubMed ID: 1515426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
    Kohler PC; Hank JA; Moore KH; Storer B; Bechhofer R; Hong R; Sondel PM
    Cancer Invest; 1989; 7(3):213-23. PubMed ID: 2790538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
    Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
    Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
    Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
    Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
    Caligiuri MA; Murray C; Soiffer RJ; Klumpp TR; Seiden M; Cochran K; Cameron C; Ish C; Buchanan L; Perillo D
    J Clin Oncol; 1991 Dec; 9(12):2110-9. PubMed ID: 1960552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
    Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
    Iigo M; Nishikata K; Nakajima Y; Moriyama M
    Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
    Pavone L; Andrulli S; Santi R; Majori M; Buzio C
    Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
    Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI
    J Clin Oncol; 1989 Feb; 7(2):276-84. PubMed ID: 2783732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial.
    Truitt RL; Piaskowski V; Kirchner P; McOlash L; Camitta BM; Casper JT
    J Immunother (1991); 1992 May; 11(4):274-85. PubMed ID: 1599913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.
    Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G
    Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.
    Blaise D; Viens P; Olive D; Stoppa AM; Gabert J; Pourreau CN; Attal M; Gaspard MH; Mannoni P; Jasmin C
    Eur Cytokine Netw; 1991; 2(2):121-9. PubMed ID: 1813015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
    Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
    J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.
    Ghosh AK; Dazzi H; Thatcher N; Moore M
    Int J Cancer; 1989 Mar; 43(3):410-4. PubMed ID: 2784419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
    Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
    Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
    Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
    Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
    Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
    Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma.
    Peest D; Leo R; Bloche S; Hein R; Stannat-Kiessling S; Tschechne B; Fett W; Harms P; Hoffmann L; Bartl R
    Br J Haematol; 1995 Feb; 89(2):328-37. PubMed ID: 7873383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.